Team:Wageningen UR
From 2012.igem.org
TSlijkhuis (Talk | contribs) |
TSlijkhuis (Talk | contribs) |
||
Line 59: | Line 59: | ||
We turned the Human Practices[link Human practices] into a national effort. | We turned the Human Practices[link Human practices] into a national effort. | ||
<div class="achievement-desc">By cooperating with most of the Dutch iGEM teams, we managed to have a nation-wide appearance in three major cities during the Discovery Festivals [link website R’dam]. Our team presents the science of iGEM in Rotterdam, while being analysed by a student in Applied Communication [link Paulien]. </div> | <div class="achievement-desc">By cooperating with most of the Dutch iGEM teams, we managed to have a nation-wide appearance in three major cities during the Discovery Festivals [link website R’dam]. Our team presents the science of iGEM in Rotterdam, while being analysed by a student in Applied Communication [link Paulien]. </div> | ||
+ | </div> | ||
+ | |||
+ | <div class="achievement software"> | ||
+ | Software: The Constructor | ||
+ | <div class="achievement-desc">We're not in iGEM's <a href="https://igem.org/Software">software track</a>, but still we think it is important to create and improve software tools for the iGEM community. Therefore we tried to fullfill the <a href="https://igem.org/Software#Software_Competition_Judging">medal requirements for the software track</a> with <a href="https://2012.igem.org/Team:Wageningen_UR/TheConstructor">The Constructor</a>.</div> | ||
</div> | </div> | ||
Revision as of 12:24, 20 September 2012
Abstract
A standardized tool for site specific drug delivery using Virus-Like Particles
Medicines are generally active in a non-site-specific fashion, affecting the whole patient, including healthy tissue. Therefore, we attempt to specifically target diseased areas by packaging medicines inside Virus-Like Particles (VLPs). VLPs are not infectious, as they are built solely from viral coat proteins. We designed a modular Plug and Apply system that enables modifications to these coat proteins. The system facilitates the linkage of numerous ligands to the coat protein, thereby creating site-specific carriers. After expression of coat protein genes in Escherichia coli the VLPs were assembled in vitro, yielding modified Virus-Like Particles. Medicines can be packed using the Plug and Apply system or simply by addition during VLP assembly. Concluding, VLPs can be used as universal carriers for site-specific drug delivery, allowing customization to a variety of diseases while decreasing side effects for patients during treatment.
The Constructor
An application that assists you in creating your cloning strategies for your iGEM project.